Key points from article :
Rejuvenation Technologies, backed by Khosla Ventures, secures $10.6 million for mRNA age-reversal therapy.
The lead candidate focuses on addressing telomere shortening, a key ageing mechanism.
Research by Rejuvenation shows mRNA therapy can rewind 10 years of telomere shortening.
Dr. John Ramunas, CEO, aims for a therapy taken every few years to extend the health span.
The funding will advance the company's programmes in fibrotic disease and the immune system.
Rejuvenation plans to expand its operations and bring on additional team members.
